Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below 200-Day Moving Average – Here’s Why

Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.21 and traded as low as $0.88. Eagle Pharmaceuticals shares last traded at $0.88, with a volume of 4,000 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on Eagle Pharmaceuticals in a research note on Saturday. They issued a “hold” rating for the company.

Eagle Pharmaceuticals Stock Performance

The business has a 50-day moving average price of $1.09 and a 200-day moving average price of $1.21.

Institutional Trading of Eagle Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. purchased a new position in Eagle Pharmaceuticals in the 3rd quarter valued at about $453,000. Jane Street Group LLC purchased a new position in shares of Eagle Pharmaceuticals in the third quarter valued at approximately $96,000. DGS Capital Management LLC boosted its stake in shares of Eagle Pharmaceuticals by 44.9% in the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after acquiring an additional 22,239 shares during the last quarter. Finally, RBF Capital LLC increased its position in shares of Eagle Pharmaceuticals by 11.7% during the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 14,991 shares in the last quarter. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.